Clinical data | |
---|---|
Trade names | Trelstar |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Pregnancy category |
|
ATC code | L02AE04 (WHO) QH01CA97 (WHO) |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Excretion | Kidney |
Identifiers | |
|
|
CAS Number | 57773-63-4 |
PubChem (CID) | 25074470 |
IUPHAR/BPS | 1177 |
DrugBank | DB06825 |
ChemSpider | 17290424 |
UNII | 9081Y98W2V |
KEGG | D06247 |
ChEBI | CHEBI:63633 |
ChEMBL | CHEMBL1201334 |
ECHA InfoCard | 100.165.044 |
Chemical and physical data | |
Formula | C64H82N18O13 |
Molar mass | 1311.5 g/mol |
3D model (Jmol) | Interactive image |
|
|
|
|
(what is this?) |
Triptorelin, a decapeptide (pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2), is a gonadotropin-releasing hormone agonist (GnRH agonist) used as the acetate or pamoate salts. By causing constant stimulation of the pituitary, it decreases pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH).
Triptorelin is used to treat prostate cancer.
Triptorelin is marketed under the brand names Decapeptyl (Ipsen) and Diphereline and Gonapeptyl (Ferring Pharmaceuticals). In the United States, it is sold by Watson Pharmaceuticals as Trelstar. In Iran Triptorelin is marketed under the brand name Variopeptyl.